



Paris, April 21st 2010, 8 am

Initial public offering of AB Science on NYSE Euronext

Revised terms and conditions

- **Indicative price range between 12.30€ and 13.00€ per share**
- **Size of the Offering: 726,820 existing shares and 1,305,700 newly issued shares, or 25.7 M€ (on the basis of the mid point of the initial public offering price range)**
- **An extension clause : up to 304,878 supplementary existing shares**
- **Over-allotment option : up to 350,609 supplementary existing shares**
- **Subscription period is expected to end on April 22nd 2010, for both the Public Offering and the Global Placement**
- **Final offering price expected on April 23rd 2010, and trading on Euronext Paris (Compartment B) is expected on April 26th 2010**

AB Science has revised the terms and conditions of its initial public offering and proposed listing of its shares on Euronext Paris, Compartment B.

The targeted gross proceeds from the issue of new shares during the Public Offering in France and Global Placement should be approximately 16.5 M€ (versus 20.2 M€ initially planned in the Prospectus approved by the AMF on April 07th 2010 under the number 10-084).

The Public offering in France and the Global placement will close on April 22nd 2010 at 17:00 (Paris time). The settlement and delivery is planned on April 28th 2010, and trading should start on April 26th 2010.

New terms and conditions of the Offering are as follows:

Number of shares offered in the Public Offering and Global Placement:

Offering : 2,032,520 shares offered, including 1,305,700 new shares to be issued and 726,820 existing shares to be sold, i.e. an overall amount of 25.7 M€.

Indicative price range: 12.30 € - 13.00 €

Extension clause: The number of shares offered may be increased by a maximum of 304,878 supplementary existing shares to be sold, i.e. 15% of the initial offering.

Over-allotment option: The number of shares offered may be increased by a maximum of 350,609 supplementary existing shares to be sold, i.e. 15% of the initial offering (including the Extension clause).

If the extension clause and over-allotment option are exercised, gross proceeds from the Offering should amount to 34.0 M€ (of which 16.5 M€ from newly issued shares and 17.5 M€ for the selling shareholders).

The indicative timetable of the Offering, as extended on April 20th 2010, stands as follows:

| | |
|----------------------|--|
| 21 April 2010 | Nyse Euronext notice relative to the revised terms and conditions of the Offering Release of a financial notice in the newspaper <i>la Tribune</i> |
| 22 April 2010 | Close of the OPO and the Global placement (17h Paris time) |
| 23 April 2010 | Fixing of the final Price of the Offering by the Board of Directors Nyse Euronext notice relative to the result of the OPO Press release indicating the final price and number of shares of the Offering |
| 26 April 2010 | Start of trading on Euronext Paris |
| 28 April 2010 | Settlement/delivery |
| 21 May 2010 | Deadline for exercising the Over-allotment option End of stabilization period |

Revocability of orders issued in the OPO:

Orders issued in the OPO before release of the financial notice in *La Tribune* on April 21st 2010 shall be maintained except where they are expressly revoked before April 22nd 2010 (17:00 hours Paris time). New irrevocable orders may be issued up to and including April 22nd 2010.

The French securities regulator (*l'Autorité des marchés financiers* – the AMF) granted visa n° 10-084 on April 7th 2010 to the Prospectus relating to AB Science's initial public offering, comprising its *Document de base* registered on February 10th under number I.10-006, an update of the *Document de base* filed with the AMF on April 7th and a *Note d'opération* (including the summary of the Prospectus).

Banking syndicate



Lead manager and bookrunner

Fortis Bank Nederland

Joint lead manager: Fortis Bank Nederland

Public information

The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 3 avenue George V, 75008 Paris.

Copies of the Prospectus are available free of charge from the Company and from the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus may be viewed on the websites of the Company (www.ab-science.com) and the AMF (www.amf-france.org).

The attention of investors is drawn to Section 4, "Risk Factors", contained in the *Document de base* registered with the AMF, the update of such *Document de base* filed with the AMF and to Section 2 "Risk Factors" contained in the *Note d'opération*.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. *masitinib*, a lead compound, has already been registered in veterinary medicine in Europe and is pursuing three on-going phases 3 in human medicine in pancreatic cancer, GIST and mastocytosis.

More information on AB Science's website: www.ab-science.com

**Citigate
Dewe Rogerson**

Contact

Agnès Villeret - Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr

Matthieu Pirouelle - Tel : +33 1 53 32 84 77 - matthieu.pirouelle@citigate.fr

Disclaimer

This press release, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such press release in certain jurisdiction may constitute a breach of applicable laws and regulation.

In particular:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any financial instruments in the United States. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. Any public offer of securities in the United States shall be made by means of a prospectus that may be obtained from the issuer containing detailed information regarding the Company, its management and financial statements. The Company does not intend to register this offering in all or in part or to make a public offer of securities in the United States.

This press release is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This document is directed only at (i) persons outside the United Kingdom; or (ii) persons in the United Kingdom that are "qualified investors" within the meaning of Article 2(1)(e) of Directive 2003/71/EC including any relevant implementing measure in each member state, that are also (a) persons authorised under FSMA or otherwise having professional experience in matters relating to investments and qualifying as investment professionals under article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order"); or (b) institutions or corporations qualifying as high net worth persons under Article 49(2)(a) to (d) of the Financial Promotion Order; or (c) any other persons to whom this document for the purposes of Section 21 of FSMA can otherwise lawfully be made (all such persons together being referred to as "Relevant Persons"). Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document.

This document contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Prospectus, changes in economic conditions, the financial markets or the markets in which AB Science operates.

Société Générale, acting as stabilizing agent, or any institution acting on its behalf (the "Stabilizing Agent") may, during a period of 30 days following the date on which the offering price is determined, ie, according to the indicative timetable, from April 23 to May 21, 2010, effect transactions with a view to maintaining the market price of AB Science shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation no 2273/03 of December 22, 2003. However, there is no assurance that the Stabilizing Agent will take any stabilizing action and, if begun, such stabilizing action may be interrupted at any time. Any stabilizing action may affect the price of AB Science shares and could result in market prices for the shares higher than those which might otherwise prevail.